RHEINCELL THERAPEUTICS GmbH specializes in the GMP-compliant generation of human induced pluripotent stem cells (iPS cells) from so-called HLA-homozygous cord blood units. Our focus is on setting up an iPS master cell bank under GMP conditions. This master cell bank will serve as a key production platform for the „on-demand“ generation of various cell therapeutics, such as retinal pigment epithelial cells for the treatment of age-related macular degeneration.
Our expertise covers the entire spectrum of the medically oriented iPSC workflow and is based on our long-standing expertise in human iPSC technology. This includes cellular reprogramming under GMP conditions, GMP/ATMP-grade iPSC expansion and cryopreservation, targeted genetic manipulation (optional) and directed differentiation.